Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravesical Administration of Durvalumab (MEDI4736) to Patients With High-risk, Non-muscle-invasive Bladder Cancer (NMIBC). A Phase II Study With Correlative

NCT03759496 is registered in ClinicalTrials.gov with Hellenic GenitoUrinary Cancer Group as lead sponsor.

NCT NCT03759496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03759496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravesical Administration of Durvalumab (MEDI4736) to Patients With High-risk, Non-muscle-invasive Bladder Cancer (NMIBC). A Phase II Study With Correlative
Lead sponsor
Hellenic GenitoUrinary Cancer Group
Phase
Phase 2
Overall status
Unknown status
Start date
November 15, 2018
Completion date
December 31, 2022
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer